Is this a future treatment for osteoarthritis?
The interleukin-1-beta finding is 'intriguing' and worth further study: editorial
Interleukin-1-beta is a key player in the osteoarthritis inflammatory process and inhibiting it may help slow the disease process, according to an exploratory analysis of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
Participants in the CANTOS trial who were treated with the IL-1-beta inhibitor canakinumab had a significantly lower rate of total hip or total knee replacements over an average follow-up of nearly four years.
